Skip to content
COVID19, Research Development

How did COVID-19 restrictions impact alcohol consumption in Australia?

La Trobe University < 1 mins read

 

MEDIA ALERT

29 January, 2024

How did COVID-19 restrictions impact alcohol consumption in Australia?

Experts from La Trobe University’s Centre for Alcohol and Policy Research have undertaken a longitudinal study of 775 participants, with six survey waves between April and December 2020, examining alcohol consumption in Victoria compared to the rest of Australia during the first year of the pandemic.

Among the results published in Drug and Alcohol Review today, the researchers found that

  • During the second lockdown in Victoria, there was no difference in changes in alcohol consumption between Victorians and those from other Australian states, despite only participants from Victoria being in lockdown. 
  • Pandemic restrictions had a bigger impact on consumption in high-risk drinkers than low and moderate-risk drinkers.

Comments attributable to lead-author, PhD student, Yvette Mojica Perez from the Centre for Alcohol Policy Research at La Trobe University.

“This is one of few Australian longitudinal studies that explored alcohol consumption throughout the first year of the pandemic. Interestingly, we found that participants in Victoria decreased their consumption during the first nationwide lockdown while participants from the rest of Australia reported no change in consumption compared to 2019.”

“The COVID-19 restrictions seemed to have had a bigger impact on high-risk drinkers who reported reducing their consumption, while consumption for the moderate and low risk drinkers remained relatively stable. 

Yvette Mojica-Perez is available for interview, please contact:

 

Sue Smethurst

Senior Manager, Media and Communications, La Trobe University

0418 643 520

More from this category

  • Medical Health Aged Care, Research Development
  • 06/09/2024
  • 15:19
La Trobe University

Breakthrough in the hunt for broad-spectrum malaria therapy

Scientists at La Trobe University have discovered a new antibody-like molecule which could be used in therapy to prevent infection from multiple malaria parasite species. The research, recently published in Nature Communications, found that when the molecule WD34 binds with a protein produced by malaria parasites, it inhibits their ability to infect cells at different stages of the disease. Led by Professor Michael Foley, Professor Robin Anders and PhD candidate Dimuthu Angage at the La Trobe Institute for Molecular Science (LIMS), the research also showed that WD34 can protect against several different malaria parasite species. Professor Foley said the discovery…

  • Medical Health Aged Care, Research Development
  • 01/09/2024
  • 09:00
Ipsen Australia and New Zealand

Cabometyx® (Cabozantinib) now available for eligible patients with non-clear cell renal cell carcinoma via the PBS

SEPTEMBER 1 2024: Cabometyx® (Cabozantinib), a once-daily oral medication, is now available on the Pharmaceutical Benefits Scheme (PBS) for eligible patients with Stage IV…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 30/08/2024
  • 00:05
NeuRA (Neuroscience Research Australia)

NeuRA launches world’s largest clinical trial for phantom limb pain

Key points NeuRA is now recruiting for TITAN, the world’s largest clinical trial to date into potential treatmentsphantom limb pain. Phantom limb pain is…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.